Search | Page 4 | Aplastic Anemia and MDS International Foundation

Search

Search results

  1. 2018 Bone Marrow Failure Disease Scientific Symposium

    ... and Poster Session Friday, March 23 Biology of MDS and Secondary Acute Myeloid Leukemia Non-Transplant Treatments for MDS and ...

    Page last updated 02/15/2018 - 2:39pm.

  2. Somatic HLA mutations expose the role of class I–mediated autoimmunity in aplastic anemia and its clonal complications

    ... and a predisposition to myelodysplastic syndrome (MDS) and leukemia. Although its exact pathogenesis is unknown, aAA is thought ... and metaphase cytogenetics , and more frequent secondary MDS . The finding of recurrent HLA class I mutations provides ...

    Research Article last updated 10/23/2017 - 10:56am.

  3. Foundation Update - June 2016

    ... aplastic anemia , myelodysplastic syndromes (MDS), and paroxysmal nocturnal hemoglobinuria (PNH). The two-year ... June 14, 2016, 1:00 PM EDT •  PNH:Secondary Mutations and Thrombosis; June 21, 2016, 1:00 PM EDT ...

    Article last updated 10/09/2017 - 2:54pm.

  4. Foundation Update - May 2016

    ... ; May 18, 1:00 PM EDT • What is Secondary MDS? Everything You Need to Know ;May 26, 2016, 1:00 PM EDT ... Understanding and Managing Iron Overload in MDS ; June 10, 2016, 1:00 PM EDT   Conferences ...

    Article last updated 10/09/2017 - 2:55pm.

  5. Foundation Update - November 2016

    ... about clinical trial design and the state of current MDS research. PACCT+ is a two-year demonstration project to develop and test a ... Some patients with MDS may progress to Secondary Acute Myeloid Leukemia (Secondary AML), a type of blood and bone ...

    Article last updated 10/09/2017 - 2:48pm.

  6. Foundation Update - July 2016

    ... • Growth Factors in Aplastic Anemia, MDS, and PNH ; July 19, 2016, 1:00 PM EDT ... Very Severe Aplastic Anemia • PNH: Secondary Mutations and Thrombosis • Transitioning ...

    Article last updated 10/09/2017 - 2:53pm.

  7. Romiplostim monotherapy in thrombocytopenic patients with myelodysplastic syndromes: long-term safety and efficacy

    ... 1-risk (lower risk) myelodysplastic syndromes (MDS) and thrombocytopenia , but its long-term toxicity and efficacy are ... /l. The primary endpoint was adverse event (AE) incidence. Secondary endpoints were efficacy parameters, including bleeding events and ...

    Research Article last updated 07/11/2017 - 10:22am.

  8. New data presented at ASCO on secondary MDS/AML

    ... in Breast and Ovarian Cancer Patients Cause AML and MDS? Article Source:  ... Cancer patients with secondary malignancies have limited access to data regarding the possibility of ...

    Article last updated 06/05/2017 - 9:37am.

  9. Myeloablative Versus Reduced-Intensity Hematopoietic Cell Transplantation for Acute Myeloid Leukemia and Myelodysplastic Syndromes

    ... post-random assignment based on an intent-to-treat analysis. Secondary end points included relapse-free survival (RFS) and TRM. Results ... myelodysplastic syndromes (MDS) ...

    Research Article last updated 05/02/2017 - 10:29am.

  10. Eltrombopag Added to IST Yields Encouraging Results

    ... of eltrombopag may impact the risk of clonal evolution to MDS. A small portion (10-20%) of patients with aplastic anemia can develop MDS ... data following transplant. How important are the stated secondary outcomes: overall survival, overall response, relapse, and clonal ...

    Interview last updated 05/24/2017 - 7:44am.